| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1376357 | Bioorganic & Medicinal Chemistry Letters | 2008 | 5 Pages |
Abstract
A novel α7 nAChR agonist, N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (3a, PHA-709829), has been identified for the potential treatment of cognitive deficits in schizophrenia. The compound shows potent and selective α7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
![Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity](/preview/png/1376357.png "First Page Preview: Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity")
Authors
Brad A. Acker, E. Jon Jacobsen, Bruce N. Rogers, Donn G. Wishka, Steven C. Reitz, David W. Piotrowski, Jason K. Myers, Mark L. Wolfe, Vincent E. Groppi, Bruce A. Thornburgh, Paula M. Tinholt, Rodney R. Walters, Barbara A. Olson, Laura Fitzgerald,